deltatrials
Completed OBSERVATIONAL NCT05839951

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions (STAR-T)

(STAR-T) Sequential TreAtment With Regorafenib and Trifluridine/Tipiracil (TAS-102, With or Without Bevacizumab) in Refractory Metastatic Colorectal Cancer: Real-world Outcomes in Community Clinical Practice in the USA

Sponsor: Bayer

Conditions Metastatic Colorectal Cancer (mCRC)
Interventions Bevacizumab Regorafenib (BAY73-4506, Stivarga®) TAS-102 (trifluridine and tipiracil, Lonsurf®)
Updated 21 times since 2023 Last updated: Nov 11, 2025 Started: Apr 24, 2023 Primary completion: Apr 30, 2025 Completion: Apr 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Metastatic Colorectal Cancer (mCRC), this trial is completed. The trial is conducted by Bayer and has accumulated 21 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Dec 2025 · 7 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

21 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  2. May 2025 — Dec 2025 [monthly]

    Active Not Recruiting

  3. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting

  4. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting

  5. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting

▶ Show 16 earlier versions

  1. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting

  2. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting

  3. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting

  4. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting

  5. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting

  6. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting

  7. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting

  8. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting

  9. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting

  10. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting

  11. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting

  12. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting

  13. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting

  14. Sep 2023 — Nov 2023 [monthly]

    Active Not Recruiting

  15. Jul 2023 — Sep 2023 [monthly]

    Active Not Recruiting

  16. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting

    First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations